MOTS-c is the closest thing to exercise in a syringe — a peptide encoded in mitochondrial DNA that, on metabolic demand, travels to the nucleus and reprograms gene expression. Circulating levels decline with age and track inversely with insulin resistance. It sits as the metabolic-signaling arm of the Mito Stack (with SS-31 for membrane repair and NAD+ for redox currency), supports GLP-1 protocols against fatigue, and works as a training amplifier 60–90 min pre-exercise. It mimics exercise's metabolic signal but not its mechanical loading — a complement to training, not a replacement.
What MOTS-c Is
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-C) is a 16-amino-acid peptide produced by mitochondria — part of a class called mitochondrial-derived peptides (MDPs). On metabolic demand (exercise or caloric restriction), cells release MOTS-c; it travels to the nucleus and changes gene expression so cells preferentially burn fat, spare glycogen, take up glucose without more insulin, and build new mitochondria. This is reprogramming, not stimulation.
How MOTS-c Works
It flips the same switch as exercise (AMPK activation): more mitochondria get built (biogenesis via PGC-1α), glucose handling improves without more insulin (GLUT4 translocation), and cleanup and stress tolerance increase (FOXO activation). The result resembles the metabolic posture of someone who trains consistently.
MOTS-c Benefits
Metabolic flexibility: shifts fuel preference toward fat oxidation and smooths fed/fasted transitions. Insulin sensitivity: insulin-independent glucose uptake; lower MOTS-c correlates with reduced insulin sensitivity in obese adults. Energy/physical capacity: builds mitochondria; late-life treatment in mice (≈70 human years) raised physical capacity and healthspan. Aging/longevity: levels decline with age; Okinawan centenarians carry a functional MOTS-c polymorphism (m.1382A>C).
| Profile | Why MOTS-c helps |
|---|---|
| Hyperglycemic | Opens alternate glucose-uptake pathway bypassing insulin resistance |
| Hypoglycemic | Shifts fuel toward fat, reducing crash frequency |
| Low-energy adults | Builds new mitochondria, increases oxidative capacity |
| Aging individuals | Restores declining MOTS-c, improves physical capacity |
| Athletes | Enhances metabolic adaptation to training |
Dosage and Protocol
SubQ or IM. Reconstitute with isotonic BAC water (with sodium chloride) — plain BAC water causes painful injection reactions. See the reconstitution calculator.
| Standard protocol | |
|---|---|
| Dose | 5–10 mg (some use 2–5 mg) |
| Frequency | 1–3×/week |
| Timing | Morning, fasted or 60–90 min before Zone-2 exercise |
| Cycle | 4–6 weeks on, 2–4 weeks off |
| Practitioner | Dose | Frequency | Duration |
|---|---|---|---|
| Ben Greenfield | 10 mg | 1×/week | Up to 10 weeks/year |
| Dr. William Seeds | 5 mg | 3×/week → 1×/week | 4–6 weeks |
| Dr. Rob Kominiarek | 10 mg | 1×/week | 4 weeks |
| Jay Campbell | 2–5 mg | Every 3rd day or weekly | Variable |
No consensus — start lower (5 mg). MOTS-c acts over hours, not weeks; morning dosing before cardio aligns with its exercise-mimetic mechanism.
GLP-1 fatigue
GLP-1 agonists shift metabolism rapidly toward fat oxidation, which is more mitochondrially demanding than glucose burning — straining mitochondria already near capacity, producing the "tired but wired" fatigue users report. MOTS-c raises oxidative capacity (AMPK, PGC-1α) so the instruction to burn fat reaches machinery that can execute. Dose 5 mg, 2–3×/week on worst-fatigue mornings; do NOT mix with GLP-1 in the same syringe.
NAD+ synergy
Fat oxidation, the electron transport chain, and sirtuins all consume NAD+. If NAD+ pools are depleted, the MOTS-c signal arrives at a system that can't execute. MOTS-c acts over hours; oral NAD+ precursors take days, so injectable (IV/IM) NAD+ — which peaks within the dosing window — is treated as co-architecture, not optional.
SS-31 priming
Emerging consensus: prime with SS-31 (repairs membrane "hardware") before MOTS-c (activates adaptive "software").
What Users Report
Energy is the primary but variable signal — boosts within ~30 min for responders, crashes for others. MTHFR caution: MOTS-c inhibits the folate cycle (AICAR accumulates, activating AMPK; 5-MTHF and methionine drop), so MTHFR carriers (C677T, A1298C) can crash harder — start 2–3 mg once weekly and pair with methyl donors (methylfolate 400–800 mcg, methyl-B12 1–2 mg, glycine 3 g). Responder phenotype: works best for metabolically compromised, older, sedentary, or GLP-1-fatigued individuals; already-lean biohackers respond less. "Spicy" injection: burning/welts from hypotonic BAC water — fixed with isotonic. Stability and fat-loss claims circulating in forums are unverified single anecdotes.
Side Effects and Safety
Well tolerated in published data. Common: injection-site reactions, mild early fatigue, transient GI discomfort. No serious adverse events in published literature to date. Do NOT mix with GLP-1 agonists in the same syringe (precipitation).
Clinical Research
| Study | Population | Finding |
|---|---|---|
| Nat Commun (2021) | Young men | Skeletal-muscle MOTS-c rises ~12-fold after exercise |
| Rev Cardiovasc Med (2022) | Elite athletes | Higher baseline MOTS-c and exercise-responsive increases |
| J Investig Med (2018) | Obese adults | Lower MOTS-c correlated with reduced insulin sensitivity |
| Eur Rev Med Pharmacol Sci (2022) | CAD patients | Lower circulating MOTS-c predicted coronary artery disease |
| Diabetes Res Clin Pract (2016) | m.1382A>C carriers | mtDNA variant affecting MOTS-c tracks with metabolic health |